Natalie Grinshtein

Natalie Grinshtein

Company: Fusion Pharmaceuticals

Job title: Director – Research


Combination of IGF-1R Targeted Alpha Therapy with Immune Checkpoint Inhibitors Results in Durable Tumour Regression in Colorectal Mouse Model 11:30 am

Fusion utilizes targeted alpha therapy (TAT) which enables delivery of alpha particle emitting isotopes (actinium 225) to the targeted tumour cells Discussing the rationale for combining TAT with immunotherapy and will give examples of the work we have done in CT26 syngeneic mouse model I will also discuss the mechanism of action behind our therapeutic…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.